# CORT · 10-Q

- Kind: Filing note
- Ticker: CORT
- Company: CORCEPT THERAPEUTICS INC
- Form: 10-Q
- Filed: 2026-07-29
- Accession: 0001628280-26-050613
- Canonical: https://edgartracker.problemsolversguild.com/s/CORT/2026-07-29/_aDM4yS1ryNFBb7eZew9Zg
- Updated: 2026-10-15T18:06:01.004073Z

---

[AI summary · GPT 4o mini · full]

## Executive summary
Corcept Therapeutics (CORT) reported strong Q2 2026 financial results with significant revenue growth, driven by the launch of Lifyorli™. However, a decline in current assets raises liquidity concerns, compounded by ongoing legal challenges that could impact future performance.

## What matters
- **Product Revenue Growth**: Q2 2026 product revenue reached $256.1 million, up 31.7% from $194.4 million in Q2 2025, indicating strong market demand.
- **Net Income Increase**: Net income rose to $42.9 million from $35.1 million year-over-year, reflecting effective cost management despite rising operating expenses.
- **Liquidity Concerns**: Current assets fell to $439.7 million from $485.5 million, primarily due to a $54.5 million drop in short-term marketable securities, signaling potential cash flow issues.
- **FDA Approval**: Lifyorli™ was approved in March 2026 for treating platinum-resistant ovarian cancer, enhancing revenue potential and expanding the product portfolio.
- **Legal Risks**: A newly filed securities class action and ongoing patent litigations, including a ruling favoring Teva's generic version of Korlym, pose significant risks to financial stability and market position.

## What's new vs context
- **Lifyorli™ Launch**: The approval and subsequent sales of Lifyorli™ represent a new revenue stream since the last filing.
- **Legal Developments**: The filing of a securities class action and the appellate court ruling on Teva's generic Korlym are new risks that were not present in prior filings.
- **Cash Position**: The decrease in cash and marketable securities is a notable change from previous filings, indicating a shift in liquidity status.

## Risks & open questions
- Monitor cash flow trends in relation to rising operating expenses and revenue growth.
- Watch for updates on the FDA review of relacorilant, with a target date of December 17, 2026.
- Keep an eye on the outcomes of ongoing legal challenges, particularly the securities class action and antitrust litigation.
- Assess the market response to Lifyorli™ sales and its impact on overall revenue.

## Bottom line
Investors should remain cautious due to liquidity concerns and legal risks, while also recognizing the potential upside from Lifyorli™'s market performance. Monitoring upcoming financial disclosures and legal developments will be crucial for assessing the investment outlook.